市場進入的影響 (歐洲主要5個國家):類風濕性關節炎 (RA)
Market Access Impact: [RA] Rheumatoid Arthritis (EU5) 2017
|市場進入的影響 (歐洲主要5個國家):類風濕性關節炎 (RA) Market Access Impact: [RA] Rheumatoid Arthritis (EU5) 2017|
|出版日期: 2017年11月01日||內容資訊: 英文||
本報告提供歐洲主要5個國家 (EU5:法國、德國、義大利、西班牙、英國) 從事類風濕性關節炎 (RA)治療的150名醫療專家的問卷調查結果，提供RA治療藥的利用相關問題點相關分析，主要企業的市場佔有率結構，及各公司現在面臨的主要障礙 (市場進入等) 與原因、影響，應採取對策的資訊彙整，為您概述為以下內容。
Eliminating market barriers could help one brand almost double its market share
Market barriers have a modest but significant effect on rheumatoid arthritis (RA) prescriptions in the EU5. The brands that can find a way to eliminate them stand to make important share gains. Especially in the middle of the market, where competition is lively, and at the bottom of the market, where certain brands are poised to nearly double market share.
Find out which barriers are costing your brand market share in: Market Access Impact: Rheumatoid Arthritis (EU5).
Based on a survey of 150 rheumatologists, the report covers 12 major therapies from AbbVie, Biogen, Bristol-Myers Squibb, Merck Sharp & Dohme, Mundipharma, Napp, Pfizer, Roche, and UCB. Handy graphs and charts show you how 7 barriers affect your market share, revealing which competitors you gain share from, and lose it to.
Not your market? Click here to see the US Edition.
Request sample pages
Insight into 12 major RA drugs
Exploring Market Access Barriers
Market Access Impact: Market Access Impact: Rheumatoid Arthritis (EU5) explores key issues affecting drug manufacturers. You'll learn:
How barriers affect market access:
How barriers affect your brand:
A Report Based on Expert Knowledge
We surveyed 150 rheumatologists-30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world.
We conducted the survey between November 3-9, 2017.
Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Learn more at www.firstwordgroup.com.